## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPE	ROVAL
OMB Number:	3235-0287
Estimated average	burden
houre par reenonee	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	pe Response	5)															
	nd Address of garet Smit	f Reporting Person* h	Person * 2. Issuer Name and Ticker or Trading Symbol Tonix Pharmaceuticals Holding Corp. [TNXP]			_x_1	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director10% Owner										
	NIX PHAR	(First) RMACEUTICAI SON AVENUE		3. Date 05/04			ansa	ction (Month	n/Day/Y	Year)	(	Officer (give t	itle below)	Other	(specify below)		
NEW YO	ORK, NY	(Street) 10022		4. If Amendment, Date Original Filed(Month/Day/Year)			_X_ For	6. Individual or Joint/Group Filing/Check Applicable Line) _X_Form filed by One Reporting Person _Form filed by More than One Reporting Person									
(Cit	y)	(State)	(Zip)				Tab	le I - Non-D	erivat	ive Securities	Acquired, D	isposed o	f, or Benefi	cially Owned	ally Owned		
1.Title of S (Instr. 3)  Reminder:		separate line for eacl	2. Transaction Date (Month/Day/Yes	Execution Date, if Code (A) or Disposed of (D) Owned Following Reported Ownership of In					Beneficial Dwnership Instr. 4)								
			Table I					cquired, Di	sposed	valid OMB of of, or Benefic	cially Owned						
1. Title of Derivative Security (Instr. 3)	2. 3. Transaction 3A. Deemed 4. 5. Number 6. Date Exercisable and		of Underlyi Securities	. Title and Amount f Underlying ecurities Instr. 3 and 4)		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	Security: Direct (D or Indirect)	Beneficial Ownershi (Instr. 4)									
							4,							Transaction(	s) (I)	t	
				Code	V	and 5)	(D)	Date Exercisable		Expiration Date	Title	Amount or Number of Shares				et .	

#### **Reporting Owners**

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Bell Margaret Smith C/O TONIX PHARMACEUTICALS HOLDING CORP. 509 MADISON AVENUE, SUITE 1608 NEW YORK, NY 10022	X					

#### **Signatures**

/s/ Jessica Morris, Attorney-in-Fact	05/06/2020
**Signature of Reporting Person	Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a)
- (1) The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.